Redhill Biopharma is a publicly traded company trading on NASDAQ, led by CEO Dror Ben-Asher.
Upcoming earnings announcement for Redhill Biopharma
Past 12 earnings reports for Redhill Biopharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Sep 5, 2025 | H1 2025 | $0.00 | — | $4.1M | — | — |
| Apr 10, 2025 | FY 2024 | $0.00 | — | $8.0M | — | — |
| Aug 29, 2024 | H1 2024 | $0.00 | — | $2.6M | — | — |
| Apr 8, 2024 | FY 2023 | $0.25 | — | $6.5M | — | — |
| Aug 17, 2023 | Q2 2023 | $2.25 | — | $1.8M | — | — |
| Jun 12, 2023 | Q1 2023 | -$1.25 | — | $3.6M | — | — |
| Apr 28, 2023 | Q4 2022 | $0.00 | — | $12.8MEst: $18.1M | -29.3% | — |
| Nov 29, 2022 | Q3 2022 | -$60.00 | — | $17.6MEst: $21.2M | -17.4% | — |
| Nov 7, 2022 | Q2 2022 | -$20.00 | — | $18.3M | — | — |
| Jun 23, 2022 | Q1 2022 | -$300.00Est: -$230.00 | -30.4% | $18.2MEst: $24.3M | -25.0% | — |
| Mar 17, 2022 | Q4 2021 | -$500.00Est: -$330.00 | -51.5% | $22.1MEst: $24.1M | -8.3% | — |
| Nov 30, 2021 | Q3 2021 | -$500.00Est: -$210.00 | -138.1% | $21.6MEst: $24.5M | -11.9% | — |
We use cookies for analytics. See our Privacy and Cookie Policy.